Condition: Congenital Adrenal Hyperplasia (CAH)
Biomarker: 17-hydroxyprogesterone (17-OHP)
The 17-OHP (17-hydroxyprogesterone) assay is intended for the quantitative determination of 17-OHP concentrations in dried neonatal whole blood specimens. Measurement of 17-OHP is used as a primary screen in the diagnosis and treatment of classical congenital adrenal hyperplasia (CAH) in newborns, an inborn error of cortisol hormone production.
For more information, visit Congenital Adrenal Hyperplasia
• 30-day prepared reagent stability – Reduced reagent prep frequency
• Options of 3 hour or overnight assay protocols – Flexible timeline to fit your laboratory’s needs
• Single plate elution allows for semi-plexing with other immunoassays – Reduced microplate usage with efficient workflow
• Multi-analyte calibrators and controls in DBS format – Simplified workflow with complementary assays
For In Vitro Diagnostic Use. This device is intended for use by trained, qualified laboratory personnel.
PRODUCT ORDERING INFORMATION
SPOTCHECK® NEONATAL 17-OHP MICROPLATE REAGENT KIT CONFIGURATIONS
|85-2000-05K/KE||5 Plate||Dried blood spot calibrators and controls, antibody coated microplates, all reagents|
|85-2000-20K/KE||20 Plate||Dried blood spot calibrators and controls, antibody coated microplates, all reagents|